Hope end of 2023

Hope end of 2023 Just for your information. A new study phase 2b. ​ [Noema Pharma announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b study of PDE10A inhibitor gemlapodect (NOE-105) in Childhood Onset Fluency Disorder | Noema Pharma](https://noemapharma.com/2022/06/27/noema-pharma-announces-fda-investigational-new-drug-ind-authorization-for-orpheus-phase-2b-study-of-pde10a-inhibitor-gemlapodect-noe-105-in-childhood-onset-fluency-disorder/)